Revive Therapeutics and Ehave Announce Patient Data Collaboration

Revive Therapeutics (TSXV:RVV; OTCQB:RVVTF) and Ehave (OTCQB:EHVVF) announced a patient research data collaboration agreement.

As quoted in the press release:

The collaboration agreement will leverage Ehave’s core expertise in health informatics through its Ehave Connect platform.  Revive will integrate the Ehave Connect solution of diagnostic and treatment tools with its ongoing research initiatives in liver disease to improve the lives of patients.  Ehave Connect will collect and integrate patient data from clinical systems, licensed health surveys, and Ehave’s own patient- and clinician-reported outcome applications, empowering users with an end-to-end patient management solution, allowing for better treatment decisions across teams and disciplines while keeping patients informed and engaged throughout their healthcare journey.

“We are very excited with our collaboration with Ehave as it provides us with a foundation of employing next generation patient and clinical research data management solutions early on in the research and development phase of our liver disease program,” said Craig Leon, Chief Executive Officer of Revive.  “Ehave’s Platform will support our research and clinical decisions and it will allow us to make objective, data-driven decisions throughout the course of our research and may provide unique insights to expand our initiatives with cannabinoids for the potential treatment of liver diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and fibrosis.”

Click here to read the full press release.

Source: globenewswire.com